PHPo-Hsun Huang

Po-Hsun Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Po-Hsun Huang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Hsin-You Ou

    Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

    8 shared publications
  • Yu-Fan Cheng

    Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

    7 shared publications
  • Cheng

    Department of Diagnostic Radiology, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Chang Gung Medical College, Niao-Sung, Kaohsiung, Taiwan

    4 shared publications
  • Leo Leung-Chit Tsang

    Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

    4 shared publications
  • Chao-Long Chen

    Liver Transplantation Program, Department of Surgery, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, Taiwan

    3 shared publications
  • Ching-Chun Weng

    Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

    3 shared publications

Latest Publications

  • Open Access

    Tumor Burden Thresholds Associated with Successful Downstaging After Yttrium-90 Radioembolization in Hepatocellular Carcinoma Beyond UCSF Criteria

    by Chun-Hua Chiu, Chun-Yen Yu, Hsin-You Ou, Leung-Chit Tsang, Po-Hsun Huang, Ching-Chun Weng, Yi Lu, Chao-Long Chen, Yu-Fan Cheng

    Purpose: Hepatocellular carcinoma (HCC) is frequently diagnosed at advanced stages, limiting access to curative therapies. Yttrium-90 (Y-90) trans-arterial radioembolization (TARE) has been used for tumor downstaging to enable surgical resection or liver transplantation; however, the factors associated with successful downstaging and potential selection thresholds remain unclear. Patients and Methods: We retrospectively analyzed 65 patients with unresectable HCC exceeding the University of California, San Francisco (UCSF) criteria who underwent Y-90 TARE between 2020 and 2024. Tumor burden parameters, dosimetric features, treatment response, overall survival (OS), and progression-free survival (PFS) were evaluated. Receiver operating characteristic (ROC) analysis was performed to identify exploratory thresholds associated with successful downstaging, and survival outcomes were assessed using Kaplan–Meier methods. Results: Down-staging to within UCSF criteria was achieved in 58.5% of patients. Successfully down-staged patients had significantly longer OS than non-downstaged patients (median OS, not reached vs. 18.8 months; p = 0.034). ROC analysis identified exploratory tumor burden thresholds associated with downstaging failure, including largest tumor diameter ≥ 7.8 cm, tumor volume ≥ 265 cm3, and a composite tumor number–diameter score > 11. The presence of multiple adverse tumor burden factors was associated with a high likelihood of downstaging failure. When adequate tumor radiation delivery was achieved, a tumor-to-normal uptake ratio (T/N) > 4 predicted successful downstaging in tumors < 7.8 cm, whereas its prognostic value diminished in larger lesions. Conclusion: Y-90 TARE enables effective downstaging in a substantial proportion of patients with advanced HCC and may facilitate subsequent curative surgery or living donor liver transplantation. Tumor burden metrics and size-dependent T/N ratios were associated with successful downstaging and may assist patient selection for Y-90 TARE. These findings should be considered exploratory and warrant validation in larger prospective studies.

  • Open Access

    Feasibility of Single-Session Whole-Liver Yttrium-90 Radioembolization for Multifocal Hepatocellular Carcinoma

    by Po-Hsun Huang, Hsin-You Ou, Leung-Chit Tsang, Hsien-Wen Hsu, Wei-Xiong Lim, Tung-Liang Huang, Ching-Chun Weng, Yi Lu, Chien-Chin Hsu, Chao-Long Chen, et al.

    Huang PH, et al. Korean J Radiol. 2026 Sep;27(9):890-896. https://doi.org/10.3348/kjr.2026.0364

  • Open Access

    Applying Intraoperative Portal Venography in Liver Transplantation Vascular Surgery

    by Szu-Kai Wang, Yu-Fan Cheng, Wei-Xiong Lim, Chao-Long Chen, Leung-Chit Tsang, Chun-Yen Yu, Hsien-Wen Hsu, Po-Hsun Huang, Chun-Hua Chiu, Hsin-You Ou

    Background/Aim: Adequate portal inflow is essential for liver graft regeneration following transplantation. Intraoperative portal venography (IOPV) provides real-time assessment of portal vein patency, stenosis, thrombus formation, and portosystemic collaterals. In addition to imaging, portal vein pressure gradient (portal vein pressure minus inferior vena cava pressure) was also measured. This study assessed the impact of IOPV on surgical decision-making and post-transplant outcomes to establish criteria for patient selection. Methods: From November 2016 to November 2024, 34 liver transplant patients with portal inflow insufficiency (flow velocity < 10 cm/s), large shunts (>1 cm), or portal vein thrombosis underwent IOPV. Of the patients, one received deceased donor liver transplantation (DDLT), and the others received living donor liver transplantation (LDLT). Preoperative computed tomography (CT) and ultrasound (US) assessed portal vein patency, thrombus, and shunts. Postoperative US and CT monitored portal flow and graft regeneration. Results: IOPV influenced surgical planning in all cases, leading to shunt ligation or stenting, and improved portal vein flow velocity from 6.3 (IQR, 0–9.0) to 30.8 (IQR, 22.2–36.7) cm/s (p < 0.001). Adequate inflow was achieved in 32 patients, 2 had persistent low flow or occluded flow owing to severe adhesion after transplant and failure to close large collateral veins. Graft regeneration ranged from 104% to 255% within a year. Conclusions: IOPV is a valuable tool in liver transplantation vascular surgery, optimizing surgical strategies and portal inflow. Early integration into routine practice may improve graft outcomes. Further prospective, longitudinal research is needed to refine patient selection and assess long-term benefits.

  • Open Access

    Efficacy and Safety of Combined Ethanol-Lipiodol Mixture and Drug-Eluting Bead TACE for Large HCC

    by Yi-Hsuan Chuang, Yu-Fan Cheng, Leo Leung-Chit Tsang, Hsin-You Ou, Hsien-Wen Hsu, Wei-Xiong Lim, Po-Hsun Huang, Ching-Chun Weng, Chun-Yen Yu

    Purpose: To evaluate treatment response, survival and safety of a novel TACE using combination of ethanol-Lipiodol mixture and drug-eluting beads in patients with large unresectable HCC, single tumor > 8 cm or multiple tumors with the largest tumor diameter > 5 cm and total tumor diameter > 10 cm. Patients and Methods: Between June 2016 and February 2020, a total of 27 patients were enrolled in this retrospective cohort study. Treatment response was assessed at first month after the treatment; progression-free survival (PFS) and overall survival (OS) were evaluated. The prognostic factors associated with patient survival were statistically analyzed by the Cox regression model. Adverse events were recorded. Results: The maximum diameter of the tumors ranged from 5 cm to 17 cm (mean 10.48 cm). The objective response and disease control rates were 56% and 78%, respectively, at 1-month follow-up. The median survival time was 15.9 months (95% CI, 9.03– 34.76 months). The OS rates were 76.9% at six months, 65.2% at one year and 44.8% at two years. AFP > 400 ng/mL (p = 0.0306), maximum tumor size > 10cm (p = 0.0240) were potential risk factors for OS. Regarding safety, major complications occurred in one patient (1/27, 3.7%), presenting with transient hepatic encephalopathy. Conclusion: Combined DEB-TACE appeared to have favorable objective tumor response. It can be an effective treatment option for large unresectable HCC.


  • Open Access

    Yttrium-90 Radioembolization as the Major Treatment of Hepatocellular Carcinoma

    by Chun-Yen Yu, Po-Hsun Huang, Leo Leung-Chit Tsang, Hsien-Wen Hsu, Wei-Xiong Lim, Ching-Chun Weng, Tung-Liang Huang, Chien-Chin Hsu, Chao-Long Chen, Hsin-You Ou, et al.

    Background: The purpose of this study was to assess the safety and efficacy of Yttrium-90 radioembolization using in unresectable hepatocellular carcinoma. Methods: From 2017 to 2021, 32 patients with unresectable hepatocellular carcinoma, with mean tumor diameter about 7cm (21 males, 11 females; median age, 57.5 years of age), treated with Yttrium-90 radioembolization using resin microspheres were reviewed at pre-Yttrium-90 and post-Yttrium-90 follow-up. Tumor response was assessed according to the modified Response Evaluation Criteria in Solid Tumors. Outcomes including overall survival and progression-free survival were reported. Results: Median follow-up was 18 months. At follow-up examinations at 3-, 6-, and 12-months follow-up, the overall survival rates were 94%, 87% and 59%, and the progression-free survival rates were 78%, 64% and 60%, respectively. Complete response, partial response, stable disease, and progressive disease were noted in 7 (21.9%), 14 (43.7%), 4 (12.5%), and 7 (21.9%) patients, respectively. The disease control rate was 78.1%, the objective response rate was 65.6%, and the successful downstage rate was 34.4% (11 of 32). Nine of thirty-two patients underwent resection or transplantation after Yttrium-90 radioembolization with 2-year overall survival being 100%. No serious adverse events occurred after Yttrium-90 treatment. Worse overall survival was related to the larger tumor, higher stage, Eastern Cooperative Oncology Group performance status, and Child-Pugh score. And worse progression-free survival was related to the higher tumor burden, and pre-Yttrium-90 serum α-fetoprotein level > 100. Conclusion: Yttrium-90 Radioembolization can control hepatocellular carcinoma well even in advanced diseases. Patients successfully downstaging/bridging to resection or transplantation have excellent overall survival.


  • Open Access

    A Scoring System for Predicting Microvascular Invasion in Hepatocellular Carcinoma Based on Quantitative Functional MRI

    by Chien-Chang Liao, Yu-Fan Cheng, Chun-Yen Yu, Leung-Chit Leo Tsang, Chao-Long Chen, Hsien-Wen Hsu, Wan-Ching Chang, Wei-Xiong Lim, Yi-Hsuan Chuang, Po-Hsun Huang, et al.

    Microvascular invasion (MVI) in hepatocellular carcinoma (HCC) is a histopathological marker and risk factor for HCC recurrence. We integrated diffusion-weighted imaging (DWI) and magnetic resonance (MR) image findings of tumors into a scoring system for predicting MVI. In total, 228 HCC patients with pathologically confirmed MVI who underwent surgical resection or liver transplant between November 2012 and March 2021 were enrolled retrospectively. Patients were divided into a right liver lobe group (n = 173, 75.9%) as the model dataset and a left liver lobe group (n = 55, 24.1%) as the model validation dataset. Multivariate logistic regression identified two-segment involved tumor (Score: 1; OR: 3.14; 95% CI: 1.22 to 8.06; p = 0.017); ADCmin ≤ 0.95 × 10−3 mm2/s (Score: 2; OR: 10.88; 95% CI: 4.61 to 25.68; p = 0.000); and largest single tumor diameter ≥ 3 cm (Score: 1; OR: 5.05; 95% CI: 2.25 to 11.30; p = 0.000), as predictive factors for the scoring model. Among all patients, sensitivity was 89.66%, specificity 58.04%, positive predictive value 68.87%, and negative predictive value 84.41%. For validation of left lobe group, sensitivity was 80.64%, specificity 70.83%, positive predictive value 78.12%, and negative predictive value 73.91%. The scoring model using ADCmin, largest tumor diameter, and two-segment involved tumor provides high sensitivity and negative predictive value in MVI prediction for use in routine functional MR.


  • Open Access

    Non-Contrast-Enhanced and Contrast-Enhanced Magnetic Resonance Angiography in Living Donor Liver Vascular Anatomy

    by Chien-Chang Liao, Meng-Hsiang Chen, Chun-Yen Yu, Leung-Chit Leo Tsang, Chao-Long Chen, Hsien-Wen Hsu, Wei-Xiong Lim, Yi-Hsuan Chuang, Po-Hsun Huang, Yu-Fan Cheng, et al.

    Background: Since the advent of a new generation of inflow-sensitive inversion recovery (IFIR) technology, three-dimensional non-contrast-enhanced magnetic resonance angiography is being used to obtain hepatic vessel images without applying gadolinium contrast agent. The purpose of this study was to explore the diagnostic efficacy of non-contrast-enhanced magnetic resonance angiography (non-CE MRA), contrast-enhanced magnetic resonance angiography (CMRA), and computed tomography angiography (CTA) in the preoperative evaluation of living liver donors. Methods: A total of 43 liver donor candidates who were evaluated for living donor liver transplantation completed examinations. Donors’ age, gender, renal function (eGFR), and previous CTA and imaging were recorded before non-CE MRA and CMRA. CTA images were used as the standard. Results: Five different classifications of hepatic artery patterns (types I, III, V, VI, VIII) and three different classifications of portal vein patterns (types I, II, and III) were identified among 43 candidates. The pretransplant vascular anatomy was well identified using combined non-CE MRA and CMRA of hepatic arteries (100%), PVs (98%), and hepatic veins (100%) compared with CTA images. Non-CE MRA images had significantly stronger contrast signal intensity of portal veins (p < 0.01) and hepatic veins (p < 0.01) than CMRA. No differences were found in signal intensity of the hepatic artery between non-CE MRA and CMRA. Conclusion: Combined non-CE MRA and CMRA demonstrate comparable diagnostic ability to CTA and provide enhanced biliary anatomy information that assures optimum donor safety.


  • Noncontrast Magnetic Resonance Angiography Clinical Application in Pre–Liver Transplant Recipients With Impaired Renal Function

    by Po‐Hsun Huang, Chien‐Chang Liao, Meng‐Hsiang Chen, Tung‐Liang Huang, Chao‐Long Chen, Hsin‐You Ou, Yu‐Fan Cheng

    Image evaluation of the vascular architecture is essential before living donor liver transplantation (LDLT). However, the use of contrast‐enhanced study in recipients with impaired renal function is limited due to the risk of acute kidney injury and nephrogenic systemic fibrosis. Therefore, a contrast medium–free method is both valuable and necessary for preoperative vascular evaluation. Recent literature reported inflow‐sensitive inversion recovery (IFIR) magnetic resonance angiography (MRA) without the use of a contrast medium to be a reproducible and noninvasive tool to assess hepatic vasculature with adequate‐to‐good image quality. The purpose of this study is to clinically apply IFIR MRA preoperatively in LDLT recipients. We retrospectively reviewed 31 LDLT recipients with renal function impairment from March 2013 to August 2018 who received IFIR MRA as a pretransplant vascular architecture evaluation and who underwent a subsequent LDLT. The image findings were assessed for subjective image quality and were compared with intraoperative findings. Our results showed that the pretransplant vascular anatomy was well correlated with intraoperative findings in all recipients. Successful ratings with image quality scores ≥2 for proper hepatic arteries (PHAs), portal veins, and inferior vena cavas (IVCs) were 100.0%, 96.8%, and 93.5%, respectively. Readable ratings with imaging quality score ≥1 for left and right hepatic arteries and gastroepiploic arteries were 83.9%, 96.7%, and 22.6%, respectively. We also found that recipients with higher Model for End‐Stage Liver Disease scores (>23) had lower image quality scores for PHAs (P = 0.003) and IVCs (P = 0.046). However, images were still satisfactory for pre–liver transplantation (LT) vascular evaluation. In conclusion, in pre‐LT recipients with impaired renal function, IFIR MRA is a feasible and reproducible image modality.